Vishnu Yelamanchi, MD
Interventional Cardiology · The Villages, FLNPI 1992788467
Payments from drug & device makers
Across 358 payments — averaging $131.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$35K
- Penumbra, Inc.$3K
- Medtronic$2K
- Boston Scientific$881
- Abbott$841
- AstraZeneca$616
- plus $5K from 32 others
What the payments were for
- Travel & lodging$2,8366%
- Food & beverage$9,16019%
- Education$140%
- Other$35,08374%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 8 | $35,207 |
| Penumbra, Inc. | 27 | $2,715 |
| Medtronic(2 entities) | 35 | $1,821 |
| Boston Scientific | 25 | $881 |
| Abbott | 29 | $841 |
| AstraZeneca | 25 | $616 |
| Novartis | 36 | $532 |
| Johnson & Johnson | 27 | $430 |
| Cvrx, Inc. | 3 | $424 |
| Abiomed | 9 | $382 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $344 |
| Amgen | 18 | $332 |
| Pfizer | 14 | $254 |
| Impulse Dynamics (USA) Inc. | 2 | $237 |
| Reflow Medical Inc | 4 | $221 |
| Cardiovascular Systems Inc. | 13 | $199 |
| Lexicon Pharmaceuticals, Inc. | 9 | $171 |
| Boehringer Ingelheim | 7 | $164 |
| Merck | 8 | $142 |
| E.r. Squibb & Sons, L.L.C. | 3 | $140 |
| Kestra Medical Technology Services, Inc. | 1 | $128 |
| Edwards Lifesciences | 2 | $123 |
| Sanofi-aventis U.S. LLC | 7 | $106 |
| Inari Medical, Inc. | 1 | $97 |
| Bard Peripheral Vascular, Inc. | 4 | $94 |
| Cordis US CORP. | 4 | $85 |
| Esperion Therapeutics, Inc. | 3 | $64 |
| Actelion Pharmaceuticals US, Inc. | 2 | $57 |
| Cook Medical LLC | 3 | $51 |
| Irhythm Technologies, Inc. | 3 | $47 |
| Siemens Medical Solutions USA, Inc. | 2 | $41 |
| Philips North America LLC | 2 | $34 |
| Atricure, Inc. | 1 | $25 |
| Biosense Webster, Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Teleflex LLC | 1 | $21 |
| Contego Medical, Inc | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$35,083
- COREVALVE EVOLUT R$1,297
- Indigo$1,172
- Indigo System$1,154
- JETSTREAM$482
- Barostim Neo System$424
- OPTIMIZER$353
- FARXIGA$249
- ESPRIT$150
- Impella$147
- Penumbra System$137
- Assure WCD$128
- CardioMEMS HF System$117
- LifeVest$117
- CAMZYOS$109
How this compares
$47,093 in reported general payments places this provider in the 75th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 266 | $352,306 |
| XareltoRivaroxaban | 53 | $73,404 |
| EntrestoSacubitril/Valsartan | 31 | $48,124 |
| Repatha SureclickEvolocumab | 33 | $36,028 |
| BrilintaTicagrelor | 28 | $28,680 |
| FarxigaDapagliflozin Propanediol | 15 | $13,540 |
| ClopidogrelClopidogrel Bisulfate | 278 | $3,772 |
| Metoprolol Succinate | 227 | $3,442 |
| Diltiazem 12hr ErDiltiazem Hcl | 16 | $2,469 |
| Atorvastatin Calcium | 181 | $2,114 |
| Rosuvastatin Calcium | 106 | $1,823 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 41 | $1,718 |
| Metoprolol Tartrate | 179 | $1,604 |
| Carvedilol | 83 | $928 |
| Lisinopril | 93 | $834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $254 | $352,306266 claims |
| Johnson & JohnsonXarelto | $430 | $73,40453 claims |
| NovartisEntresto | $532 | $48,12431 claims |
| AstraZenecaBrilinta, Farxiga | $616 | $42,22043 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in The Villages
- Hector GarciaThe Villages$724K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.